Rheumatoid arthritis and the heart

Current Heart Failure Reports

Volumn 3, Issue 2, 2006, Pages 57-63

  Kremers, Hilal Maradit ^b   Gabriel, Sherine E ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CORTICOSTEROID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE ASSOCIATION; HEART FAILURE; HEART PROTECTION; HOMOCYSTINURIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT;

ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; EPIDEMIOLOGIC STUDIES; HEART DISEASES; HUMANS; INCIDENCE; RISK FACTORS;

EID: 33750310895     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-006-0003-0     Document Type: Review

References (49)

1. Frostegard J: Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005, 25:1776-1785. A comprehensive overview of potential mechanisms that may contribute to accelerated atherosclerosis in systemic lupus erythematosus and RA.
2. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
3. Diwan A, Tran T, Misra A, Mann DL: Inflammatory mediators and the failing heart: a translational approach. Curr Mol Med 2003, 3:161-182.
4. Maradit Kremers H, Gabriel SE: Epidemiology. In Rheumatoid Arthritis. Edited by St. Clair EW, Pisetsky DS, Haynes BF. Philadelphia: Lippincott Williams & Wilkins; 2004:1-10.
5. Gabriel SE, Crowson CS, O'Fallon WM: Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999, 26:2529-2533.
6. Gonzalez A, Maradit Kremers H, Crowson CS, Gabriel SE: Survival trends and risk factors for mortality in rheumatoid arthritis. Int J Advances Rheum 2005, 3:38-46.
7. Gabriel SE, Crowson CS, O'Fallon WM: Comorbidity in Arthritis. J Rheumatol 1999, 26:2475-2479.
8. del Rincon ID: High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737-2745.
9. Solomon DH, Karlson EW, Rimm EB, et al.: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303-1307.
10. Maradit-Kremers H, Crowson CS, Nicola PJ, et al.: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005, 52:402-411. This comprehensive long-term study demonstrated for the first time that silent myocardial infarctions and sudden deaths are more common in RA patients compared with control subjects.
11. Nicola PJ, Maradit-Kremers H, Roger VL, et al.: The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005, 52:412-420. A comprehensive long-term study that demonstrates that HF is more common in RA patients compared with control subjects and that RF positive patients have a much higher risk.
12. Kumeda Y, Inaba M, Goto H, et al.: Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:1489-1497.
13. Park YB, Ahn CW, Choi HK, et al.: Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002, 46:1714-1719.
14. Del Rincon I, Williams K, Stern MP, et al.: Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003, 48:1833-1840.
15. Roman MJ, Moeller E, Davis A, et al.: Preclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis. Ann Intern Med 2006, 144:249-256.
16. Aubry MC, Maradit-Kremers H, Reinalda MS, et al.: Differences in atherosclerotic coronary heart disease between patients with and without rheumatoid arthritis: an autopsy study of 123 cases [abstract]. Arthritis Rheum 2005, 52:S153.
17. Aubry MC, Riehle DL, Edwards WD, et al.: B-Lymphocytes in plaque and adventitia of coronary arteries in two patients with rheumatoid arthritis and coronary atherosclerosis: preliminary observations. Cardiovasc Pathol 2004, 13:233-236.
18. Bergholm R, Leirisalo-Repo M, Vehkavaara S, et al.: Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002, 22:1637-1641.
19. Hurlimann D, Forster A, Noll G, et al.: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106:2184-2187.
20. Hermann F, Forster A, Chenevard R, et al.: Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 2005, 45:461-464.
21. Solomon DH, Curhan GC, Rimm EB, et al.: Cardiovascular risk factors in women with and without rheumatoid arthritis. Arthritis Rheum 2004, 50:3444-3449.
22. Gonzalez A, Maradit-Kremers H, Nicola PJ, et al.: The incidence of cardiovascular risk factors in rheumatoid arthritis [abstract]. Arthritis Rheum 2005, 52:S324.
23. Park YB, Choi HK, Kim MY, et al.: Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002, 113:188-193.
24. Escalante A, Haas RW, del Rincon I: Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005, 165:1624-1629.
25. Kremers HM, Nicola PJ, Crowson CS, et al.: Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004, 50:3450-3457.
26. Choi HK, Hernán MA, Seeger JD, et al.: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177. This well-designed database study is the first to demonstrate that methotrexate use is associated with a significantly lower risk of cardiovascular mortality in RA patients.
27. Davis JM 3rd, Maradit-Kremers H, Gabriel SE: Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? J Rheumatol 2005, 32:1856-1862.
28. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528.
29. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety. JAMA 2000, 284:1247-1255.
30. Fitzgerald GA: Coxibs and cardiovascular disease. N Engl J Med 2004, 35:1709-1711. Review article that summarizes potential mechanisms for increased risk of cardiovascular disease with COX-2 inhibitors.
31. Maradit-Kremers H, Nicola PJ, Crowson CS, et al.: Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005, 52:722-732.
32. Danesh J, Collins R, Peto R, Lowe GD: Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 2000, 21:515-520.
33. Swanberg M, Lidman O, Padyukov L, et al.: MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005, 37:486-494.
34. McCarey DW, McInnes IB, Madhok R, et al.: Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363:2015-2021.
35. Mutru O, Laakso M, Isomaki H, Koota K: Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 1989, 76:71-77.
36. Wolfe F, Freundlich B, Straus WL: Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003, 30:36-40.
37. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al.: Echocardiographic and Doppler findings in long-term treated rheumatoid arthritis patients without clinically evident cardiovascular disease. Semin Arthritis Rheum 2004, 33:231-238.
38. Suskin N, Sheth T, Negassa A, Yusuf S: Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol 2001, 37:1677-1682.
39. Dessein PH, Stanwix AE, Joffe BI: Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res 2002, 4:R5.
40. Crowson CS, Nicola PJ, Kremers HM, et al.: How much of the increased incidence of heart failure in rheumatoid arthritis is attributable to traditional cardiovascular risk factors and ischemic heart disease? Arthritis Rheum 2005, 52:3039-3044. The authors use attributable risk statistics and demonstrate that the risk of HF attributable to traditional risk factors is less in RA patients compared with non-RA patients.
41. Davis JM 3rd, Maradit-Kremers H, Crowson CS, et al.: Cumulative glucocorticoid exposure and the risk of cardiovascular events in a population-based cohort of rheumatoid arthritis subjects [abstract]. Paper submitted to the ACR 2005 Annual Meeting. San Diego, CA November 13-17, 2005.
42. Mann DL: Mechanisms and models in heart failure: A combinatorial approach. Circulation 1999, 100:999-1008.
43. Khanna D, McMahon M, Furst DE: Anti-tumor necrosis factor alpha therapy and heart failure: what have we learned and where do we go from here? Arthritis Rheum 2004, 50:1040-1050.
44. Wolfe F, Michaud K: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am Med 2004, 116:305-311.
45. Heerdink ER, Leufkens HG, Herings RM, et al.: NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998, 158:1108-1112.
46. Garcia Rodriguez LA, Hernandez-Diaz S: Nonsteroidal antiinflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003, 14:240-246.
47. Mamdani M, Juurlink DN, Lee DS, et al.: Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004, 363:1751-1756.
48. Maradit Kremers H, Crowson CS, Nicola PJ, et al.: Erythrocyte sedimentation rate (ESR) and congestive heart failure (CHF) in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2004, 50:S557-S558.
49. Nicola P, Maradit Kremers H, Crowson C, et al.: Systemic lupus erythematosus (SLE) characteristics in rheumatoid arthritis subjects are associated with the risk of congestive heart failure (CHF). Arthritis Rheum 2004, 50:S551.